Skip to main content
AIOBIO Co., Ltd. logo

AIOBIO Co., Ltd. — Investor Relations & Filings

Ticker · 447690 ISIN · KR7447690009 KO Manufacturing
Open in API
Filings indexed 88 across all filing types
Latest filing 2024-12-11 Regulatory Filings
Country KR South Korea
Listing KO 447690

About AIOBIO Co., Ltd.

https://www.aiobio.com/

AIOBIO Co., Ltd. is a medical device company specializing in advanced dental care solutions. The company develops and manufactures diagnostic tools and platforms based on its proprietary Biofluorescence-Led Intelligent Screening System (BLISS) technology. Its product portfolio includes imaging devices that provide instant visual analysis for the early detection of oral health issues. AIOBIO's core offering is the LINKDENS platform, an integrated system that connects dental clinics and patients. Powered by AI-driven diagnostics, instant imaging analysis, and remote patient monitoring, LINKDENS streamlines clinical workflows, enhances diagnostic accuracy, and fosters a connected dental care experience for both professionals and patients.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short notice regarding the setting of a record date for the purpose of determining shareholders eligible to attend the 14th Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a regulatory notification of a corporate action related to shareholder rights and meeting preparation. Given the nature of the announcement, it fits best under general regulatory filings.
2024-12-11 Korean
기업설명회(IR)개최결과
Regulatory Filings Classification · 100% confidence The document is a short, structured announcement reporting the results of an Investor Relations (IR) event held on November 14, 2024. It provides details such as the date, location (online platforms), attendees, and a summary of the topics covered, while directing readers to the Korea IR Association website for the actual presentation materials. Since this is a brief notification of an event's occurrence rather than the presentation itself, it falls under the category of a regulatory announcement regarding corporate activities.
2024-11-15 Korean
기타주요경영사항(자율공시) (미국식품의약국(FDA) 의료기기(2등급) 품목허가 취득 (치아우식증 진단 보조 장비))
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement from a Korean company (IOBIO) regarding the receipt of FDA approval for a medical device. It is categorized as a 'Major Management Matter' (기타 주요경영사항) under the Korean regulatory disclosure system. Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a general regulatory disclosure of a material business event, it falls under the 'Regulatory Filings' (RNS) category.
2024-09-05 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and a subsequent correction (정정신고) filed with the Financial Supervisory Service/Korea Exchange. This type of filing is a standard regulatory disclosure for capital structure changes and financing activities in the Korean market. It fits the 'Capital/Financing Update' category as it details the terms of a bond issuance, use of proceeds, and investor information.
2024-07-02 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) by AIOBIO Co., Ltd. This is a regulatory filing required by the Korea Exchange (KRX) to disclose significant corporate financing activities. Since it details the terms of a capital raise through debt instruments that can be converted into equity, it falls under the 'Capital/Financing Update' category.
2024-07-01 Korean
증권발행결과(자율공시) (제1회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the issuance method, the amount (4 billion KRW), the payment date, and the nature of the transaction (offsetting existing loans). This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2024-07-01 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.